Pharma / Biotech

Activity-guided development of potent and selective toll-like receptor 9 antagonists.

Related Articles

Activity-guided development of potent and selective toll-like receptor 9 antagonists.

Eur J Med Chem. 2018 Sep 26;159:187-205

Authors: Paul B, Rahaman O, Roy S, Pal S, Satish S, Mukherjee A, Ghosh AR, Raychaudhuri D, Bhattacharya R, Goon S, Ganguly D, Talukdar A

Abstract
TLR9 is one of the major innate immune receptors expressed in the endosomes of pDCs and B cells in humans. Aberrant TLR9 activation is implicated in several autoimmune and metabolic disorders as well as in sepsis, making this receptor an important therapeutic target, though specific TLR9 antagonists are yet to be available for clinical use. Here we elucidate the importance of specific physiochemical properties through substitution patterns in quinazoline scaffold to achieve potent hTLR9 inhibition at < 50 nM as well as > 600 fold selectivity against hTLR7, another closely related TLR that shares downstream signaling with TLR9 but plays distinct roles in physiology and pathology. Assays were performed using hPBMC and reporter cell lines. Favorable in vitro ADME profile, pharmacokinetics as well as validation in a clinically relevant in vivo TLR9-inhibition efficacy model in mice establish these novel TLR9-antagonists as candidate therapeutic agents in relevant clinical contexts.

PMID: 30292896 [PubMed – as supplied by publisher]

Source link




Related posts

MAXIMUM STRENGTH RANITIDINE (Ranitidine) Tablet [Winco Foods, LLC.]

Newsemia

SULFAMETHOXAZOLE AND TRIMETHOPRIM Tablet [NuCare Pharmaceuticals,Inc.]

Newsemia

Mesoderm/mesenchyme homeobox gene l promotes vascular smooth muscle cell phenotypic modulation and vascular remodeling.

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy